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 Lipoprotein(a)-cholesterol (Lp(a)-C), a low-density lipoprotein (LDL)-like 
particle is considered as a risk factor for cardiovascular diseases (CVDs).  
We aimed to investigate the association of Lp(a)-C expression with 
dyslipidemia among the Bangladeshi population and assess the relationship 
with cardiovascular risks. In this cross-sectional comparative study, a total of 
180 urban males and females between ages 19-65 years were included who 
were enrolled in a hospital setting of Bangladesh. Participants were selected 
based on their total cholesterol (TC) level≥200 mg/dl, high density 
lipoprotein (HDL)-C<40 mg/dl, LDL-C≥140 mg/dl, and triacylglycerol 
(TG)≥150 mg/dl regardless of race, religion and socioeconomic status. 
Venous blood was collected from all participants and analyzed.  
Further, participants’ socio-demographics and body mass index (BMI) were 
collected. Expression of Lp(a)-C was detected in 22.86% patients with 
desirable levels (<14 mg/dL) of serum Lp(a)-C. This study suggests that the 
prevalence of hyperlipidemia and hypertriglyceridemia is high in the 
Bangladeshi population. Males were found to have lower HDL-C and higher 
TG than females. and, similar to other ethnic groups, a negative correlation 
between BMI and HDL-C was found in this population. In addition, Lp(a)-C 
had a positive correlation with TG which may recommend routine clinical 
investigation of Lp(a)-C as a biomarker for CVD risk. 
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1. INTRODUCTION  
Dyslipidemia refers to an abnormal amount of lipids or fats carried by lipoproteins in the blood [1]. 
According to WHO, dyslipidemia is a highly prevalent disorder (38.9%) in the worldwide [2] that is 
associated with decreased longevity and increased morbidity resulting from a wide range of pathological 
conditions, including insulin resistance, obesity, hypertension, cardiovascular diseases (CVDs),  
and atherosclerosis [3]. The lipids that are commonly measured in blood include various forms of cholesterol,  
such as high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), 
triglycerides (TGs) as well as total cholesterol (TC). Though lipids are essential to life, an abnormal amount 
of certain lipids can increase the risks for CVDs [4-5]. For example, HDL-C is known as  
the “good cholesterol,” but its lower level may increase the risk of CVDs. On the other hand, LDL-C,  
known as the “bad cholesterol,” is linked to increased risk of heart attacks and strokes [6]. 
Lipoprotein(a)-cholesterol (Lp(a)-C) is an LDL-like particle in which apolipoprotein(a),  
a glycoprotein consisting of several repetitive kringle IV type 2 (KIV-2) structures and homology to 
plasminogen [7], is attached to apolipoprotein B by a disulphide linkage [8]. High levels of Lp(a)-C in blood 
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can create plaque, a buildup of cholesterol that limits blood flow through arteries. Elevated concentrations of 
Lp(a)-C has been identified as the strongest risk factor for CVDs in the general population [9]. Variations in 
the levels of Lp(a)-C are mainly genetically determined [10] in which the level of Lp(a)-C is inversely 
correlated with the number of KIV-2 [11]. Lp(a)-C concentration can also vary from population to population 
[12-13]. Other factors such as diet, drugs, hormones and glycemic control are also found to affect Lp(a)-C 
concentration [14]. Previous in vitro, animal, and epidemiological studies suggest controversial results that 
Lp(a)-C may contribute to the development of atherosclerosis or thrombosis and thus increase the frequencies 
of myocardial infarction and ischemic heart diseases [15-18]. 
According to the world health report in 2003, CVDs were responsible for more than 80% of deaths 
in South Asia, which is 40-60% higher than any other population [19]. Different studies have found 
improvement from CVDs by lowering the cholesterol levels [20-21]. However, most of the dyslipidemic 
studies in Bangladesh are focused on the relationship with diabetes [22-24] and sufficient data is not 
available for the assessment of cardiovascular risks with dyslipidemia. This study therefore aims to 
investigate the expression of Lp(a)-C in Bangladeshi dyslipidemic patients and their relation to the risks of 
CVDs. To the best of our knowledge, there is lack of evidence on expression of Lp(a)-C levels among the 
Bangladeshi population. 
 
 
2. RESEARCH METHOD  
2.1.  Study design and participants 
We conducted a cross-sectional comparative study among 180 males and females from July 2015 to 
June 2016. Of these subjects, 140 males and females were dyslipidemic and 40 males and females were  
non-dyslipidemic, which served as the comparison group. We selected urban residing population aged 19-65 
years. The study was carried out in a hospital setting, approximately 24 km away from Dhaka-capital of 
Bangladesh. Dyslipidemic subjects with cholesterol≥200 mg/dl, HDL-C<40 mg/dl, LDL-C≥140 mg/dl,  
and TG≥150 mg/dl were recruited in this study irrespective of race, religion and socioeconomic status. 
Hyperlipidemia (high levels of TC and TG), hypertriglyceridemia (high levels of TG),  
atherogenic dyslipidemia (high levels of TG, LDL-C, low levels of HDL-C) and hypercholesterolemia  
(high levels of TC) were considered as different types of dyslipidemia. 
 
2.2.  Variable assessed 
Data on age (in years), gender (male/female), physical exercise (yes/no), dietary habit  
(consumption of red meat three times or more per week: yes/no), smoking (yes/no), history of diabetes 
mellitus (yes/no), and hypertension (HTN: yes/no) were collected by interviewing participants. Physical 
exercise was defined as at least 30 minutes of planned physical movement to improve one’s fitness [25]. 
Individuals having more than five cigarettes per day was considered a positive smoking condition [26]. 
Valid cases of diabetes mellitus and HTN were considered by those who have been earlier diagnosed by  
a registered physician and provided the prescription. Body weight of the subjects was measured (to the 
nearest 0.1 Kg) by standing motionless on a digital weighing machine. Height was measured (to the nearest 
0.1 cm) by Leicester Height Measure. Body Mass Index (BMI) (expressed in kg/m2) was calculated and 
categorized as follows: underweight<18.5, normal weight 18.5-24.9, overweight 25-29.9;  
and obese>30 [27]. According to the guideline of the Joint National Commission on Prevention, Detection, 
Evaluation, and Treatment of High Blood pressure (BP) (JNC 7), participant’s systolic blood pressure 
(SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg was considered as HTN [28]. BP was 
measured by using a digital blood pressure monitor machine (©OMRON Healthcare Europe B.V) after the 
subject was rested for 10 minutes in the sitting position. We repeated the BP measurements three times in 10 
minutes interval. 
 
2.3.  Collection of blood samples 
Overnight fasting (8-10 hours) venous blood was collected between 8:00-9:00 am. Venous blood  
(5 ml) was obtained by the hospital phenologist using venipuncture following the standard procedure.  
The blood was taken in a plain tube and allowed to clot for 30 minutes. Serum was separated by 
centrifugation for 10 min at 3000 rpm using a refrigerated centrifuge and used for further biochemical 
analyses. The lipid profiles (TC, HDL-C, LDL-C, TG) were measured using an Automatic Analyzer  
(QCA mini Discrete Random- Access Analyzer, Spain). 
 
2.4.  Estimation of Lp(a)-C 
Overnight fasting (8-12 hours) blood samples were taken in a plain tube and allowed to clot for 30 
minutes. Serum was separated by centrifugation to detect the expression of Lp(a)-C using the Helena 
Int. J. Public Health Sci. ISSN: 2252-8806  
 
Detection of lipoprotein(a)- cholesterol expression in Bangladeshi adults with dyslipidemia (Puja Biswas) 
289 
BioSciences SAS-1 Cholesterol Profile-12 Kit (Helena BioSciences, UK) Manufacturer provided protocol 
was used for gel electrophoresis. The SAS-1 Cholesterol Profile-12 Kit separates serum lipoproteins 
according to charge in a buffered agarose gel. The alpha band, which migrates fastest towards the anode, 
corresponds to HDL. The next band, prebeta, corresponds to VLDL and the slowest moving beta band 
corresponds approximately to LDL. A band may appear between the alpha and pre-beta bands on some,  
but not all, samples-this should be quantitated as the Lp(a)-C fraction. Gels were scanned using a 570nm 
filter and expression levels of Lp(a)-C were analyzed densitometrically using platinum.exe software. 
 
2.5.  Statistical analysis 
Both descriptive and inferential statistics were used in this study. Continuous variables were 
presented as mean±standard deviation (SD) and the statistical difference between groups was assessed by 
Independent Sample’s T-test and Analysis of variance (ANOVA) followed by Fisher's least significant 
difference (LSD) post hoc. Paired samples correlation was performed to calculate measure correlation. 
Significance level was set at <0.05. Statistical Package for Social Sciences (SPSS) software,  
version 13 was used. 
 
 
3. RESULTS AND DISCUSSIONS  
In Bangladesh, though most of the studies on dyslipidemia investigate the different levels of lipid 
components, the pattern of dyslipidemia and Lp(a)-C expression in dyslipidemic subjects has not specifically 
been studied. In this study, we focus on the pattern of dyslipidemia associated with compounding risk factors 
like age, gender, BMI, hypertension, which can complicate the risk of CVDs. Also, the expression of Lp(a)-C 
in dyslipidemic subjects was detected to associate with CVDs. Based on the laboratory findings of abnormal 
lipid profiles of the out patients, dyslipidemic subjects were included in this study. 
To evaluate dyslipidemia as a risk factor for CVDs in Bangladeshi population, at first, we examined 
the BMI, systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the study subjects. 
Dyslipidemic patients had significantly higher BMI, SBP and DBP compared to non-dyslipidemic patients as 
shown in Table 1. This indicates that dyslipidemic patients are at a higher risk for CVD events than  
non-dyslipidemic subjects. Moreover, the level of HDL-C was significantly lower which is known as one of 
the risk factors for CVDs [29-30] and TG was significantly higher in dyslipidemic subjects compared to  
non-dyslipidemic subjects. 
 
 
Table 1. Variation in BMI, BP and lipid profiles between dyslipidemic and non-dyslipidemic group 
Variables 
Mean±(SD) 
P value*† 
Dyslipidemic (N 140) Non-dyslipidemic (N 40) 
BMI (kg/m2) 25.74±4.57 23.39±3.57 0.004* 
Blood pressure 
   
SBP (mmHg) 137.11±15.82 115.57±8.9 0.000* 
DBP (mmHg) 88.82±11.25 73.81±7.08 0.000* 
Lipid components 
   
TC (mg/dL) 199.78±44.50 184.75±36.24 0.052 
HDL-C (mg/dL) 35.98±10.25 44.70±12.85 0.000* 
LDL-C (mg/dL) 117.07±37.46 110.33±35.21 0.311 
TG (mg/dL) 235.08±166.1 148.58±74 0.000* 
†Independent Sample’s t-test 
*p=<0.05 
 
 
The differences between genders in individuals with dyslipidemia and status of individual lipid 
components are presented in Table 2. The level of HDL-C was significantly lower in males compared to their 
counterpart, whereas the TG is significantly higher in males compared to females. This indicates that males 
are more prone to becoming dyslipidemic and are therefore at a high risk for CVDs [31].  
In addition, researchers found an inverse correlation between smoking and HDL-C level [32]. In our study, 
most of the males were smokers and had low levels of HDL-C. This pattern is also a risk factor for CVDs 
therefore our study suggests that CVDs are more prevalent in the male population. 
We noted that a considerable number of middle-aged populations (40-50 years) had been suffering 
from dyslipidemia compared to the young and old population; however, we did not find significant 
differences in different age groups. Although we found insignificant differences in the serum levels of the 
lipid components among the different age groups, the TG levels were higher in older ages. We noted a higher 
number of dyslipidemic patients with elevated blood pressure, although the numbers were not significantly 
different. However, a previous study has shown a positive relation between HTN and abnormal dyslipidemia 
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as well as CVDs [33]. In regard to BMI, we found that most of the dyslipidemic subjects were overweight. 
Moreover, most of the dyslipidemic males were overweight, whereas the majority of  
the females’ BMI were normal.  
Correlation of BMI of the dyslipidemic subjects with serum levels of individual lipid components 
was also analyzed. From our data, correlations of BMI with TC, LDL-C and TG were all statistically 
insignificant. However, negative correlation of BMI with HDL-C in the studied Bangladeshi population was 
highly remarkable (p=0.05) which is similar to other ethnic groups [33]. From this point of view,  
we can explain that with the increasing of BMI, good cholesterol (HDL-C) is decreasing which is associated 
with CVD risk. Advancing age, high levels of BMI, SBP, DBP and abnormal lipid profiles are considered 
risk factors for CVDs in both genders [34-35]. In our study, dyslipidemic subjects are more aged and have 
high BMI, SBP and DBP than that of normal subjects and therefore increase the risk of CVDs in their life.  
 
 
Table 2. Comparison of lipid profile based on gender, age, BP and BMI among dyslipidemic participants 
Variables TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL) 
Gender     
Male 193±44 32.9±8 110.5±38 268±181.22 
Female 207±44 40±10.5 124.6±35.6 197.16±138.5 
P value* † 0.064 0.000* 0.026* 0.011* 
Age     
19-39 years 199.5±38 36.2±9.4 118±32 212.5±105 
40-50 years 202.6±43.7 36.9±10 118.2±35.8 240.8±180 
51-65 years 196.2±51.3 35.3±10.3 114.7±44.4 248±192 
P value* » 0.778 0.739 0.883 0.586 
Blood pressure     
Normotensive 194.05±36.6 35.85±8.71 116.91±29.98 202.97±146.28 
Hypertensive 202.77±48.02 36.44±10.49 117.16±40.98 251.83±173.88 
P value* † 0.273 0.738 0.970 0.083 
Correlation with BMI (r/‘p’ value)# 0.057/0.502 -0.166/0.050 0.069/0.416 0.011/0.901 
†Independent Sample’s t-test  
»ANOVA followed by Fisher's least significant difference (LSD) post hoc 
# Paired samples correlation 
*p=<0.05 
 
 
Next, it is detected the expression level of Lp(a)-C by agarose gel electrophoresis using the Helena 
BioSciences SAS-1 Cholesterol Profile Kit (Helena BioSciences, UK). Expression of Lp(a)-C was detected 
among 22.9% (n=32) of 140 dyslipidemic subjects in this study (data not shown). Among them, 31.25% were 
female and 68.75% were male. The mean Lp(a) level was 9.36±6 mg/dL (Data not shown). The reference 
values for Lp(a)-C are: Desirable<14 mg/dL (<35 nmol/L), Borderline risk 14-30 mg/dL (35-75 nmol/L), 
High risk 31-50 mg/dL (75-125 nmol/L), and very high risk>50 mg/dL (>125 nmol/L) [36-37].  
From this reference, we found desirable Lp(a)-C levels in our studied population.  
Most of the Lp(a)-C containing dyslipidemic subjects were above 40 years. As shown in Table 3, 
differences in the level of lipid components among the different age groups were insignificant but the levels 
of TC, TG and LDL-C were relatively higher in the 40-50 years age group. The HDL-C levels in serum were 
significantly higher in the females compared to the males. Although statistically insignificant (p=0.277), 
serum levels of TG in male subjects were higher than that of female subjects. In terms of TC, HDL-C,  
LDL-C, no significant correlation was found with Lp(a)-C level. However, there was significant positive 
correlation between TG and Lp(a)-C level (r=0.423, p=0.016).  
Lp(a)-C is thought as an independent risk factor for CVDs, and thereby association between the 
level of Lp(a) and TG is controversial [38-39]. Though the number of Lp(a)-C containing subjects in our 
study was low, based on our findings it may be a notable risk factor for CVDs in this population.  
Moreover, the positive correlation between Lp(a)-C and TG levels may recommend routine clinical 
investigation of Lp(a)-C as a biomarker for CVD risk. 
We also investigated different habits including smoking, exercise and red meat consumption among 
in dyslipidemic subjects and also in the subjects with Lp(a)-C expression to find out the relationship of those 
habits with the risk of development of CVDs as shown in Table 4. A large number of dyslipidemic subjects 
had higher smoking history and more consumption of red meat as shown in Table 4.  
Interestingly, Lp(a)-C expression levels were also found to be associated with living style. Previous report 
showed that smoking lowers the level of HDL-C [32]. Though diet has a lesser effect on Lp(a)-C,  
different studies showed that  pecan, walnuts and fish oil can lower the level of Lp(a)-C [39-41].  
Moreover, previous findings also supported a direct association between consumption of red meat and  
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CVDs [42-43]. As red meat increases the level of plasma TG [44], it may increase the risk of CVDs in 
subjects with Lp(a)-C. 
 
 
Table 3. Lipidemic status of dyslipidemic subjects with Lp(a)-C expression 
Variables TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL) 
Gender 
Male 190±37.6 33.35±6.4 106.15±35.31 268.5±108.5 
Female 196±46.7 42±12.2 107.5±40.2 226±79 
P value* † 0.697 0.011* 0.921 0.277 
Age 
19-39 years 201.1±35 35±10 117.7±31 220.5±65 
40-50 years 192.8±39 35.2±8.8 104±38.1 288.2±114.8 
51-65 years 183±47.4 38.6±10.7 102.7±38.8 223.5±84.8 
P value* » 0.677 0.655 0.669 0.183 
Correlation Between 
Lp(a)-C and Lipid 
Profile (r/‘p’ value)*# 
0.032/0.864 0.135/0.461 (-)0.156/0.394 0.423/0.016* 
†Independent Sample’s t-test  
»ANOVA followed by Fisher's least significant difference (LSD) post hoc 
# Paired samples correlation 
*p=<0.05 
 
 
Table 4. Demographic distribution of the study participants 
Factor Habit Dyslipidemic subjects (n=140) Lp(a)-C subjects (n=32) 
Smoking 
No 32.9% (46) 34.4% (11) 
Yes 67.1% (94) 65.6% (21) 
Exercise 
 
No 50% (70) 40.6% (13) 
Yes 50% (70) 59.4% (19) 
Red Meat 
No 47.1% (66) 43.8% (14) 
Yes 52.9% (74) 56.3% (18) 
Frequency is expressed as %(N) 
 
 
CVDs are major health problems throughout the world and a common cause of premature morbidity 
and mortality in South Asia [19]. Early diagnosis of dyslipidemia can decrease the probability of morbidity 
and mortality caused by CVDs. However, Lp(a)-C remains an enigmatic lipoprotein though it had been 
identified more than 50 years ago by Kare Berg [45], and prior to the discovery of the genetic sequence of 
apo(a) over 20 years ago by McLean et al [7]. Although a risk factor role of Lp(a)-C for CVDs has been 
controversial, recent studies have supported the role of Lp(a)-C in promoting CVDs. In our study, both male 
and female dyslipidemic subjects with Lp(a)-C expression commonly displayed hyperlipidemia and 
hypertriglyceridemia. Although statistically insignificant, serum level of TG in male subjects was higher than 
that of the female subjects, and TC was higher in females compared to males. Most of the Lp(a)-C expressing 
subjects were overweight and in age between 40-50 years. The TG level in this age was also high. Most of 
the dyslipidemic subjects with Lp(a)-C expression had hypertension which is similar to other studies [46-47]. 
The positive correlation between Lp(a)-C and TG level can be explained by the association of Lp(a)-C 
containing particle apo(a) with plasma TG [48]. These findings indicate that dyslipidemic subjects with 
Lp(a)-C expression are more prone to experience CVDs in their life.  The strength of this study includes 
direct collection of blood and analysis of the samples. Despite the strength, the study has a couple of 
limitations. One limitation of our study was that we did not measure the Lp(a)-C level of the control subjects 
in order to compare it to the Lp(a)-C level in dyslipidemic subjects. This gap can be included in future work 
and more research is needed to investigate the prevalence of Lp(a)-C in a wide range of the Bangladeshi 
population. Another limitation is the disproportionate number of individuals in the comparison and target 
groups (140 vs 40), however it would unlikely affect the results as we have analyzed the biological samples 
and reported biological variations of both groups. 
 
 
4. CONCLUSION  
The research found that the prevalence of hyperlipidemia and hypertriglyceridemia is high in the 
Bangladeshi population and most of the Lp(a)-C expression is found in the dyslipidemic group, which may 
be considered as a risk factor for CVDs. 
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